Key Highlights
- Autonomix Medical (NASDAQ:AMIX) is indicated at USD 1.87 pre-market on Tuesday, November 10, 2026, up 10.00% from a calculated prior close of USD 1.70, which matches the November 9 close.
- The November 9 session already gained USD 0.18, or 11.84%, on Volume of 342,889 shares in a range of USD 1.53 to USD 1.77.
- Market Capitalization is USD 3.33 million on 1.96 million shares, down 32.9%, against a 52-week range of USD 1.46 to USD 32.55.
- The company lost USD 16.11 million, or USD 36.37 per share, and the last published quarter showed cash of USD 9.9 million against a USD 30 million to USD 36 million funding need.
What Moved Autonomix Medical Pre-Market (+10.00%)
The pre-market quote of USD 1.87 is 10.00% above the USD 1.70 close on November 9, 2026, a gain of USD 0.17 per share. The stock had already risen 11.84% on Monday, so the move is a continuation of a two-day bounce rather than a fresh jump. No company release or filing dated November 9 or 10, 2026 was found, so no catalyst is identified. The latest items located were on September 30, 2026, when the company reported FDA pre-submission feedback supporting a 510(k) pathway for its standalone device, and early October 2026, when it announced a Canadian patent. Those items are weeks old and are not confirmed as the driver.
Why Small Medical Device Stocks Move Without News
As general context, pre-revenue device companies often trade on regulatory headlines, Patent news, financing and technical bounces. Autonomix develops a catheter-based nerve sensing and ablation platform, and a 510(k) pathway can shorten the route to US clearance compared with a full premarket approval. Investors also watch the cash runway: the last published quarter, ended December 31, 2025, showed a net loss of USD 3.3 million and cash of USD 9.9 million, with the company saying cash would last into the third quarter of calendar 2026. A stock with 1.96 million shares can move 10% on a few thousand shares of buying. Two analysts rate the stock Buy with an average target of USD 40.80, a figure that sits far above the Market Price and has not been tested by trading.
Valuation, Liquidity and Risks for Autonomix Medical (NASDAQ:AMIX)
At USD 1.87, the calculated Market Value is about USD 3.7 million, below the USD 9.9 million of cash reported at December 31, 2025, although the company has since burned cash and may have raised funds that this review could not confirm. The stock sits 94% below its 52-week high of USD 32.55, a calculated figure, and only 28% above its low of USD 1.46. The company needs an estimated USD 30 million to USD 36 million more to reach commercialization of its first indication, so dilution through offerings or reverse splits is the central risk. Spreads can be wide before 9:30 a.m. ET, and a Reversal remains possible. Pre-market sessions run from 4:00 a.m. to 9:30 a.m. ET, with far fewer participants than the regular session. The company is also pre-revenue, so there are no sales figures to anchor the valuation. Nothing here implies the move will continue.
Where Things Stand
Autonomix Medical (NASDAQ:AMIX) is up 10.00% pre-market with no catalyst identified in published coverage as of November 10, 2026. The shares follow an 11.84% gain on November 9, so momentum in a 1.96 million share float is the most plausible mechanic, which is general context. Funding needs and dilution risk remain the key constraints.






Please wait processing your request...